Search details
1.
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Oncologist
; 27(12): e938-e948, 2022 12 09.
Article
in English
| MEDLINE | ID: mdl-36190331
2.
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Br J Cancer
; 124(8): 1388-1397, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33531690
3.
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Liver Int
; 41(3): 598-607, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33188713
4.
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Liver Int
; 41(11): 2759-2767, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34173317
5.
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites.
Hepatol Res
; 51(6): 715-721, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33743189
6.
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Liver Int
; 40(8): 2008-2020, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32279446
7.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Lancet Oncol
; 20(8): 1109-1123, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31301962
8.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Article
in English
| MEDLINE | ID: mdl-28916371
9.
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Oncologist
; 23(12): 1407-e136, 2018 12.
Article
in English
| MEDLINE | ID: mdl-29853658
10.
RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.
Proc Natl Acad Sci U S A
; 111(4): E484-91, 2014 Jan 28.
Article
in English
| MEDLINE | ID: mdl-24434553
11.
Delta-like 1-Lysine613 regulates notch signaling.
Biochim Biophys Acta
; 1813(12): 2036-43, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21985982
12.
Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Immunotherapy
; 14(16): 1341-1351, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36285590
13.
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
Clin Cancer Res
; 28(11): 2297-2305, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35247922
14.
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.
EClinicalMedicine
; 54: 101679, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36247923
15.
Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis.
J Biol Chem
; 285(18): 13827-38, 2010 Apr 30.
Article
in English
| MEDLINE | ID: mdl-20220139
16.
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Liver Cancer
; 10(5): 451-460, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34721507
17.
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
JHEP Rep
; 3(2): 100215, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33392490
18.
STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability.
Cancer Res
; 79(7): 1465-1479, 2019 04 01.
Article
in English
| MEDLINE | ID: mdl-30482772
19.
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Clin Lung Cancer
; 19(3): 213-220.e4, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29317191
20.
p19Arf represses platelet-derived growth factor receptor ß by transcriptional and posttranscriptional mechanisms.
Mol Cell Biol
; 32(21): 4270-82, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-22907756
Results
1 -
20
de 20
1
Next >
>>